Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data

Group 1 - Vera Therapeutics, Inc. experienced a share price increase of over 65% during pre-market trading following the release of ORIGIN Phase 3 trial data [1] - Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) showed a 46% reduction in proteinuria from baseline, with a statistically significant 42% reduction compared to placebo at week 36 (p<0.0001) [1][2] - The safety profile of atacicept was favorable and comparable to that of the placebo [2] Group 2 - Vera plans to present the trial results to the FDA soon and will submit full results to the American Society of Nephrology Kidney Week [3] - The company is targeting a potential commercial launch of atacicept in 2026 [3] - The ongoing trial will continue to evaluate kidney function changes over two years, with completion expected in 2027 [4]